In 2023, the import of vaccines for human use to France stood at an estimated 1.058 billion USD. From this baseline, projected imports show a slight decrease over the forecast period. In 2024, imports are estimated at 1.0419 billion USD, decreasing further to 0.98189 billion USD by 2028. This demonstrates a consistent, modest year-on-year decline. On average, the compound annual growth rate (CAGR) reflects a downward trend over the five-year period. This trend may be indicative of various factors such as increased domestic production, shifts in vaccine demand, or changes in global supply chain dynamics.
Future trends to watch for include potential impacts from advances in vaccine technology, such as mRNA developments, shifts in global health policies, or changes in international trade agreements that could influence France's reliance on vaccine imports. Monitoring the balance of imported versus domestically-produced vaccines could also provide insights into France's strategic focus on healthcare autonomy.
